CDDO-Me has shown efficacy in multiple tumor models and has been shown to regulate activation of multiple signaling pathways implicated in carcinogenesis and cancer progression, including Nrf2, NFκB, and STAT3. The gene discussed is STAT3; the disease is cancer.